Gufic BioSciences Ltd
Gufic BioSciences Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Indore facility peak revenue expected around Rs. Indore facility expected to start EBITDA breakeven in FY '26 and become bottom-line accretive by FY '27. - Peak revenue from Indore anticipated around Rs.
From Gufic BioSciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Indore facility peak revenue expected around Rs. 800 crore by FY 2028, reaching 70%-75% capacity utilization.
- Revenue from Indore in FY 2026 projected between Rs. 100 to 150 crore, reaching EBITDA breakeven in FY 2026 and full profitability by FY 2027.
- International business expected to grow from 16%-18% to about 25% of total revenue in next 2-3 years, potentially doubling exports in 3-5 years.
- Contrast-media basket projected to contribute 5%-6% to the critical care segment within 2-3 years, expanding with new Gado-based product launches.
- Critical care segment contributes over 50% of domestic revenue; infertility around 25%.
2 more points from Gufic BioSciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gufic BioSciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indore facility is a key strategic capital investment, recently capitalized in Q3 FY '25.
- Loan of Rs. 160 crore taken for Indore plant (Rs. 100 crore from Saraswat Bank and Rs. 60 crore from HDFC Bank).
- Indore underwent extended media-fill and aseptic process validations to ensure export market compliance.
- Indore plant poised to ramp up to ~30% capacity in FY '26 to achieve EBITDA breakeven; expected to be bottom-line accretive by FY '27.
- Tech transfers initiated for 33 SKUs at Indore, with 15-18 completed, highlighting ongoing product development and capacity expansion.
- Additional product launches planned, e.g., Gado-based contrast media and new biosimilars in fertility and neurocare divisions.
2 more points from Gufic BioSciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gufic BioSciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has booked 16 major customer audits for its CMO business.
- Five global regulatory inspections have been notified, with mock inspections underway.
- Technology transfers for 33 SKUs from Navsari and 18 site transfers from other CMO partners are in progress.
- Development of 15 new products at the Indore R&D center is in advanced stages.
2 more points from Gufic BioSciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gufic BioSciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹231 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Gufic BioSciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gufic BioSciences Ltd Q4 FY25 results?
Indore facility peak revenue expected around Rs. Indore facility expected to start EBITDA breakeven in FY '26 and become bottom-line accretive by FY '27. - Peak revenue from Indore anticipated around Rs.
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a neutral. The stock trades at a P/E of 62.6 with a market cap of ₹3,955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
Indore facility is a key strategic capital investment, recently capitalized in Q3 FY '25. - Loan of Rs.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.